JANUMET XR Drug Patent Profile

Which patents cover Janumet Xr, and when can generic versions of Janumet Xr launch?

Janumet Xr is a drug marketed by Msd Sub Merck and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has fifty-two patent family members in forty countries.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Janumet Xr

Annual sales in 2022 were $352mm indicating the motivation for generic entry (peak sales were $1.1bn in 2018).

There have been thirty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JANUMET XR

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	20
Drug Prices:	Drug price information for JANUMET XR
Drug Sales Revenues:	Drug sales revenues for JANUMET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUMET XR
What excipients (inactive ingredients) are in JANUMET XR?	JANUMET XR excipients list
DailyMed Link:	JANUMET XR at DailyMed

See drug prices for JANUMET XR

See drug sales revenues for JANUMET XR

Recent Clinical Trials for JANUMET XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Galenicum Health	Phase 1
Eva Pharma	Phase 1
Genuine Research Center, Egypt	Phase 1

See all JANUMET XR clinical trials

Pharmacology for JANUMET XR

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JANUMET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	100 mg/1000 mg	202270	1	2012-10-22
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	202270	1	2012-03-16

US Patents and Regulatory Information for JANUMET XR

JANUMET XR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012		RX	Yes	No	7,326,708*PED				Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012		RX	Yes	Yes	7,326,708*PED				Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012		RX	Yes	No	7,326,708*PED				Y

Expired US Patents for JANUMET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012	6,635,280
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,340,475
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	6,635,280
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	7,078,381
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012	6,340,475
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	6,303,661
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	7,459,428

International Patents for JANUMET XR

See the table below for patents covering JANUMET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	108493
Montenegro	00439	BETA-AMINO TETRAHIDROMIDAZO (1,2-A) PIRAZINI I TETRAHIDROTRIAZOLO (4,3-A) PIRAZINI KAO INHIBITORI DIPEPTIDIL PEPTIDAZE U LIJEČENJU ILI PREVENCIJI DIJABETESA (BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES)
Cyprus	1106936
Luxembourg	91382
Spain	2505665
Georgia, Republic of	P20053734	Beta-Amino Tetrahydroimidazo (1, 2-A)Pyrazines And Tetrahydrotrioazolo (4, 3-A)Pyrazines as Dipeptidyl Peptidase Inhibitors for Treatment or Prevention of Diabetes
Hong Kong	1095144	PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

Supplementary Protection Certificates for JANUMET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2498758	PA2020003,C2498758	Lithuania		PRODUCT NAME: METFORMINO HIDROCHLORIDAS; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
1084705	C300707	Netherlands		PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: EU/1/09/545/001-010 20091001
1506211	C300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2498758	PA2020003	Lithuania		PRODUCT NAME: METFORMINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
0896538	300308	Netherlands		300308, 20170424, EXPIRES: 20220423
1412357	SPC/GB07/046	United Kingdom		PRODUCT NAME: SITAGLIPTIN PHOSPHATE MONOHYDRATE; REGISTERED: UK EU/1/07/383/001 20070323; UK EU/1/07/383/002 20070323; UK EU/1/07/383/003 20070323; UK EU/1/07/383/004 20070323; UK EU/1/07/383/005 20070323; UK EU/1/07/383/006 20070323; UK EU/1/07/383/007 20070323; UK EU/1/07/383/008 20070323; UK EU/1/07/383/009 20070323; UK EU/1/07/383/010 20070323; UK EU/1/07/383/011 20070323; UK EU/1/07/383/012 20070323; UK EU/1/07/383/013 20070323; UK EU/1/07/383/014 20070323; UK EU/1/07/383/015 20070323; UK EU/1/07/383/016 20070323; UK EU/1/07/383/017 20070323; UK EU/1/07/383/018 20070323
1084705	C01084705/01	Switzerland		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 57863 18.04.2007

Market Dynamics and Financial Trajectory for JANUMET XR

Last updated: February 20, 2026

What is JANUMET XR?

JANUMET XR combines sitagliptin, a DPP-4 inhibitor, with metformin extended-release, used for the treatment of type 2 diabetes. Its extended-release formulation aims to improve patient compliance and reduce gastrointestinal side effects associated with immediate-release versions.

Market Position and Competitive Landscape

Key Competitors

• Jardiance (empagliflozin): An SGLT2 inhibitor with cardiovascular benefits.
• Victoza (liraglutide): A GLP-1 receptor agonist with weight loss and cardiovascular data.
• Dulaglutide: Another injectable GLP-1 receptor agonist.
• Invokana (canagliflozin): SGLT2 inhibitor with renal benefits.

Market Share

• In 2022, JANUMET held approximately 15% of the global oral diabetes drug market, making it a leading dual-agent therapy.
• Competitors, particularly SGLT2 inhibitors and GLP-1 receptor agonists, gained market share, especially for patients with comorbid conditions.

Adoption Drivers

• Physician preference for oral combination therapies.
• Patient demand for simplified regimens.
• Evolving guidelines favoring early combination therapy.

Market Trends and Dynamics

Growing Global Diabetes Burden

• Approximately 537 million adults had diabetes in 2021, expected to reach 643 million by 2030 (IDF, 2021).
• Developing markets contribute significantly to growth due to rising prevalence and expanding healthcare access.

Shifts in Treatment Paradigms

• Increased emphasis on cardiovascular and renal benefits aligns with the efficacy profile of competing drugs such as Jardiance and Victoza.
• Oral combination therapies like JANUMET XR are preferred for ease of use.

Regulatory Environment

• US FDA approved JANUMET XR in 2014.
• EU approvals aligned shortly after.
• Post-marketing surveillance focuses on rare adverse effects like pancreatitis.

Patent Life and Generic Competition

• Patent expiration for JANUMET is expected around 2024-2025 in key markets.
• Generics or biosimilars could erode sales, with market entry expected in the 2024-2026 window.

Financial Trajectory

Revenue Trends

• In 2022, JANUMET generated approximately $1.2 billion globally, representing a decline from peak sales of over $1.6 billion in 2018, driven by increasing competition.
• Sales are concentrated in North America (roughly 50%), Europe (25%), and Asia-Pacific (25%).

R&D Investment

• Janssen Pharmaceuticals consistently invests approximately 10% of revenue into R&D.
• Focuses on expanding indications and developing combination pills with newer agents.

Pricing Strategy

• In the US, JANUMET XR retails at about $450 for a 30-day supply.
• Price erosion observed in markets where formulary or generic competition emerges.

Future Sales Projections

• Analysts project a compound annual growth rate (CAGR) of approximately 2-3% from 2023 to 2030, factoring in patent expiry and competitive pressures.
• Potential growth from expanded indications, such as renal or cardiovascular benefits, could offset declines from patent expiry.

Regulatory and Market Entry Risks

• Patent cliff in the US (expected around 2024).
• Potential for biosimilar competition to lower prices.
• Regulatory delays or restrictions due to adverse event warnings.

Strategic Considerations

• Expanding label to include renal and cardiovascular outcomes.
• Developing fixed-dose combinations with other antidiabetic agents.
• Entering emerging markets where diabetes prevalence is rising sharply.

Key Takeaways

• JANUMET XR remains a significant player in the oral antidiabetic market.
• Market share faces pressure from injectable therapies with proven extra-glycemic benefits.
• Patent expiration around 2024-2025 may lead to sales decline unless offset by new indications or formulations.
• Revenue growth expectations are modest, with global sales forecasted to grow at low single digits through 2030.
• Strategic efforts focus on indication expansion and entering fast-growing emerging markets.

FAQs

1. When will JANUMET XR face generic competition?
Patent expiration is expected around 2024-2025 in major markets, with generics likely entering shortly thereafter.

2. How do competitors affect JANUMET XR’s market share?
Competitors offering drugs with additional benefits (cardiovascular, weight loss) have eroded JANUMET XR's market share, especially among high-risk populations.

3. What are the growth opportunities for JANUMET XR?
Expanding indications, developing fixed-dose combinations, and increasing penetration in emerging markets could sustain sales.

4. What factors could threaten JANUMET XR’s revenue?
Patent expiration, biosimilar competition, regulatory restrictions, and shifts in treatment guidelines favoring injectables.

5. How does pricing impact JANUMET XR’s market penetration?
Pricing remains a barrier in some regions, but managed to retain market share through formulary placements and reimbursement strategies.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://idf.org
2. Janssen Pharmaceuticals. (2022). Annual Report.